Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Dillman

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Gold standard or wrong standard?Robert Oldham, Robert Dillman
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructsPatric Schiltz, Robert Dillman
Cardiovascular Diseases|March 1, 1978
PITUITARY TUMOR, QT PROLONGATION AND VENTRICULAR ARRHYTHMIALawrence J. Petrovich, Ajit V. Adyanthaya, Robert Dillman, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinomaRobert Dillman, Neil Barth, Louis Vandermolen, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomasRobert Dillman, Neil Barth, Senthamil Selvan, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2005
Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancerRobert Dillman, Patric Schiltz, Carol DePriest, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysisRobert Dillman, Senthamil Selvan, Patric Schiltz, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancer Biotherapy & Radiopharmaceuticals|August 3, 2004
Gold standard or wrong standard?Robert Oldham, Robert Dillman
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2004
A theoretical approach for T-lymphocyte monitoring of autologous cancer vaccine therapy using autologous HLA-class I and HLA-class II constructsPatric Schiltz, Robert Dillman
Cardiovascular Diseases|March 1, 1978
PITUITARY TUMOR, QT PROLONGATION AND VENTRICULAR ARRHYTHMIALawrence J. Petrovich, Ajit V. Adyanthaya, Robert Dillman, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinomaRobert Dillman, Neil Barth, Louis Vandermolen, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomasRobert Dillman, Neil Barth, Senthamil Selvan, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 25, 2005
Tumor-infiltrating lymphocytes and interleukin-2: dose and schedules of administration in the treatment of metastatic cancerRobert Dillman, Patric Schiltz, Carol DePriest, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 15, 2005
Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysisRobert Dillman, Senthamil Selvan, Patric Schiltz, et al.
Pageof 1